Home › Funds › Baader Bank Aktiengesellschaft › VRTX
Baader Bank Aktiengesellschaft position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
Baader Bank Aktiengesellschaft reported holding 11,777 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$5.8M, representing 0.68% of its reported portfolio and ranking #40 among its reported holdings. Baader Bank Aktiengesellschaft has disclosed VRTX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Baader Bank Aktiengesellschaft's VRTX position evolved
Baader Bank Aktiengesellschaft first disclosed a stake in VRTX in Q3 2023 at 1,974 shares (US$686K). The position peaked in Q4 2025 at 13,604 shares, worth US$6.2M. Across 11 filings, Baader Bank Aktiengesellschaft increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 11,777 shares valued at US$5.8M — an increase of 6,497 shares quarter over quarter.. Notable position changes include a 112% increase in Q2 2025 (shares fell 12% over the following quarter), a 61% trim in Q1 2026 (shares rose 11% over the following quarter), a 123% increase in Q2 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.97K | $685.53K | New |
| Q4 2023 | 1.51K | $614.40K | Reduce |
| Q1 2024 | 1.83K | $767.05K | Add |
| Q2 2024 | 2.39K | $1.12M | Add |
| Q3 2024 | 2.44K | $1.12M | Add |
| Q4 2024 | 2.48K | $996.75K | Add |
| Q1 2025 | 1.11K | $512.54K | Reduce |
| Q2 2025 | 2.36K | $1.05M | Add |
| Q4 2025 | 13.60K | $6.16M | New |
| Q1 2026 | 5.28K | $2.36M | Reduce |
| Q2 2026 | 11.78K | $5.85M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Invesco Ltd 8.04M sh · $4.00B · Q2 2026
- LOOMIS SAYLES & CO L P 3.92M sh · $1.95B · Q2 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- Clearbridge Investments, LLC 2.34M sh · $1.16B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.17M sh · $1.08B · Q2 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on Baader Bank Aktiengesellschaft
FAQ
How long has Baader Bank Aktiengesellschaft held VRTX?
Baader Bank Aktiengesellschaft has disclosed VRTX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
What is Baader Bank Aktiengesellschaft's current position in VRTX?
As of Q2 2026, Baader Bank Aktiengesellschaft holds 11.78K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $5.85M, representing 0.68% of its reported portfolio and ranking #40.
Has Baader Bank Aktiengesellschaft been buying or selling VRTX?
In the latest 13F filing (Q2 2026), Baader Bank Aktiengesellschaft increased its position in VRTX. The position peaked in Q4 2025 at 13.60K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.